Literature DB >> 2538828

Hepatitis B virus X gene can transactivate heterologous viral sequences.

J S Twu1, W S Robinson.   

Abstract

The smallest open reading frame of hepatitis B virus (HBV) has been designated the X gene and its biological function during HBV infection and replication is not known. Experiments described here demonstrate that expression of the HBV X gene in HepG2 cells containing a plasmid with the chloramphenicol acetyltransferase (CAT) gene under control of the human immunodeficiency virus (HIV-1) long terminal repeat (LTR) sequence leads to a marked increase in CAT gene transcription as well as expression of the gene product (CAT). The HIV-1 tatIII gene and the HBV X gene together increased HIV-1 LTR-regulated CAT expression above that observed with either gene alone, suggesting a synergistic effect of the X gene and tat. HBV X gene also stimulated expression of the CAT gene under control of the simian virus 40 enhancer and early promoter but not the visna virus LTR or the human T-cell lymphotropic virus type I (HTLV-I) LTR, indicating that the HBV X gene can transactivate some but not other heterologous viral sequences. Transactivation of the HIV-1 LTR by the HBV X gene varied in different cell lines, suggesting that it may be mediated by a cellular factor(s).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2538828      PMCID: PMC286844          DOI: 10.1073/pnas.86.6.2046

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP.

Authors:  M Imagawa; R Chiu; M Karin
Journal:  Cell       Date:  1987-10-23       Impact factor: 41.582

2.  Transcriptional trans-activating function of hepatitis B virus.

Authors:  J S Twu; R H Schloemer
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

3.  Translational control of cytomegalovirus gene expression is mediated by upstream AUG codons.

Authors:  A P Geballe; E S Mocarski
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

4.  The trans-activator gene of HTLV-III is essential for virus replication.

Authors:  A G Fisher; M B Feinberg; S F Josephs; M E Harper; L M Marselle; G Reyes; M A Gonda; A Aldovini; C Debouk; R C Gallo
Journal:  Nature       Date:  1986 Mar 27-Apr 2       Impact factor: 49.962

5.  Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA.

Authors:  C Sureau; J L Romet-Lemonne; J I Mullins; M Essex
Journal:  Cell       Date:  1986-10-10       Impact factor: 41.582

6.  HIV-1 tat trans-activation requires the loop sequence within tar.

Authors:  S Feng; E C Holland
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

7.  Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.

Authors:  M A Sells; M L Chen; G Acs
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

8.  Hepadnaviruses and retroviruses share genome homology and features of replication.

Authors:  W S Robinson; R H Miller; P L Marion
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

9.  Phorbol ester enhances human immunodeficiency virus-promoted gene expression and acts on a repeated 10-base-pair functional enhancer element.

Authors:  J D Kaufman; G Valandra; G Roderiquez; G Bushar; C Giri; M A Norcross
Journal:  Mol Cell Biol       Date:  1987-10       Impact factor: 4.272

10.  In vitro activation of the HIV-1 enhancer in extracts from cells treated with a phorbol ester tumor promoter.

Authors:  H Dinter; R Chiu; M Imagawa; M Karin; K A Jones
Journal:  EMBO J       Date:  1987-12-20       Impact factor: 11.598

View more
  51 in total

1.  Inhibition of hepatitis B virus X gene expression by novel DNA enzymes.

Authors:  R Goila; A C Banerjea
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

2.  Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis.

Authors:  X W Wang
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

3.  Increased growth of permanent mouse fibroblasts in soft agar after transfection with hepatitis B virus DNA.

Authors:  M Seifer; W H Gerlich
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Alternate translation initiation on hepatitis B virus X mRNA produces multiple polypeptides that differentially transactivate class II and III promoters.

Authors:  L Kwee; R Lucito; B Aufiero; R J Schneider
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

5.  Activation of the human immunodeficiency virus type 1 long terminal repeat by vaccinia virus.

Authors:  K A Stellrecht; K Sperber; B G Pogo
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Mutational analysis of enhancer domains responsive to trans-activation by the X gene of human hepatitis B virus.

Authors:  G Goodarzi; H Ohno; R Adams; A Darabi; A Tewari; M Watabe; K Watabe
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

7.  Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras.

Authors:  N P Klein; R J Schneider
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

8.  Detection of a hepatitis B virus variant with a truncated X gene and enhancer II.

Authors:  R Repp; C Keller; A Borkhardt; A Csecke; S Schaefer; W H Gerlich; F Lampert
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

9.  Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress.

Authors:  G Waris; K W Huh; A Siddiqui
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

Review 10.  Regulatory mechanisms of viral hepatitis B and C.

Authors:  G Waris; A Siddiqui
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.